Evidence map›Paper›PMID 35127178›Full record

ArticleAutism research and treatment2022

Effectiveness and Adverse Effects of Risperidone in Children with Autism Spectrum Disorder in a Naturalistic Clinical Setting at a University Hospital in Oman.

Salim Al-Huseini, Ali Al-Barhoumi, Miad Al-Balushi, Amira Al-Hosni, Tamadhir Al-Mahrouqi, Balqees Al-Mahrizi, Sanjay Jaju, Hassan Mirza

Abstract read
In one paragraph

Article in Autism research and treatment, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Salim Al-HuseiniPsychiatry Residency Training Program, Oman Medical Specialty Board, Muscat, Oman.ORCID https://orcid.org/0000-0002-6557-7033
Ali Al-BarhoumiColleges of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman.
Miad Al-BalushiPsychiatry Residency Training Program, Oman Medical Specialty Board, Muscat, Oman.
Amira Al-HosniDepartments of Behavioral Medicine, Sultan Qaboos University Hospital, Muscat, Oman.
Tamadhir Al-MahrouqiPsychiatry Residency Training Program, Oman Medical Specialty Board, Muscat, Oman.
Balqees Al-MahriziColleges of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman.
Sanjay JajuDepartment of Family Medicine and Public Health, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman.
Hassan MirzaDepartments of Behavioral Medicine, Sultan Qaboos University Hospital, Muscat, Oman.ORCID https://orcid.org/0000-0002-1808-8560

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed at examining the effectiveness of treating children with autism spectrum disorder (ASD) who present with irritability, aggression, and disruptive behavior at the Sultan Qaboos University Hospital (SQUH) in Muscat, Oman, with risperidone, and to note any sex-based differences among this cohort.

methodThis was a retrospective study conducted at the Department of Behavioral Medicine at SQUH over two years from January 2017 to December 2018. This study included all children aged 3 to 18 years attending the Child and Adolescent Mental Health Service (CAMHS) outpatient clinic with a diagnosis of ASD, based on the DSM-5 criteria, and comorbid disruptive behavior, who had been prescribed risperidone.

resultThis study identified 95 ASD patients (72 males). Male patients' BMI score after 12 months of risperidone treatment showed an increase by 0.62 (1.57 SD;

conclusionIn conclusion, low-dose risperidone monotherapy is effective and well tolerated among some children with ASD who present with disruptive behavior in a naturalistic clinical setting. However, we found that some of the side effects, such as weight gain and somnolence, were concerning.

Identifiers

PMID35127178
PMCPMC8814715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.